



IFW

PATENT APPLICATION

UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q93797

Yuji HOYANO, et al.

Appln. No.: 10/572,515

Group Art Unit: Not Yet Assigned

Confirmation No.: 4754

Examiner: Not Yet Assigned

Filed: March 17, 2006

For: CONCURRENT DRUGS

INFORMATION DISCLOSURE STATEMENT **UNDER 37 C.F.R. §§ 1.97 and 1.98**

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08.A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

3

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/572,515

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The ISR was filed March 17, 2006.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



/Peter D. Olexy/

Peter D. Olexy

Registration No. 24,513

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 26, 2006

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/572,515
Confirmation Number	4754
Filing Date	March 17, 2006
First Named Inventor	Yuji HOYANO
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q93797

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,541,488	B1	04-01-2003	Bernat et al.
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	2002/028827	A1	11-04-2002	Kissei Pharmaceutical Co., Ltd.	Abstract
		EP	1 331 221	A1	07-30-2003	Kissei Pharmaceutical Co., Ltd.	English
		JP	2003-104957	A	04-09-2003	Kissei Pharmaceutical Co., Ltd.	Abstract
		WO	03/000256	A1	01-03-2003	Bayer Aktiengesellschaft	Abstract
		JP	2002/504110	A	02-05-2002		Abstract
		JP	8-217692		08-27-1996	Nippon Steel Corp; Nippon Steel Chemical Co.	Abstract
		JP	90-20681		01-21-1997	Behringwerke AG; Brigham & Women's Hospital	Abstract
		EP	0 732 102	A2	09-18-1996	Behringwerke Aktiengesellschaft; Brigham and Women's Hospital	Abstract
		JP	72-58103		10-09-1995	Kiyo Yoshinari	Abstract
		DE	4432549		03-16-1995	Hur Kye Sung	Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		PANCRAS C.W., EARL J.C., OLIVER N., CAROL A.W., ADRIENNE R., Antithrombotic actions of selective inhibitors of blood coagulation factor X a in rat models of thrombosis, Thrombosis Research, 1996, Vol. 83, No. 2, pages 117 to 126, particularly, page 118, lower part to page 119, line 12, Arterio-venous shunt model, page 121, Fig. 2	English
		Yasuo IKEDA, "Kokesshobanyaku no Rinsho Koka to Tsukaikata", Medical Practice 2002, Vol. 19, No. 5, pages 839 to 844, particularly, pages 843 to 844	No

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.